Category: Epidarex Portfolio News
Originally published October 31, 2016 in Invest Edinburgh A new biotech company called Nodthera has been launched in Edinburgh to develop potential treatments for a range of diseases including Alzheimer’s. We spoke to Elizabeth Roper, a partner in Edinburgh-based equity capital specialist Epidarex… What will…
Newhouse, United Kingdom, October 26, 2016 – Clyde Biosciences today announced the launch of a new service to serve the needs of its global pharma clients. CellOPTIQ®-X represents a revolution in contractility assays, offering: Early detection of contractility toxicities Higher throughput, cost-effective solution Reduction in…
Brighton, UK, October 17, 2016 – Enterprise Therapeutics Ltd, a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases, today announced that it has appointed Dr. John Ford as CEO with immediate effect. Enterprise Therapeutics is…
Edinburgh, Scotland, October 7, 2016 – At the OBN Awards 2016 dinner in Oxford last night, Edinburgh Molecular Imaging were awarded the Best Emerging Medtech Company Award. EM Imaging CEO Ian Wilson celebrates wining the Best Emerging Medtech Company Award at OBN 2016. The Awards, which…
LOUISVILLE, Ky., Aug. 8, 2016 – Apellis Pharmaceuticals, Inc., a clinical stage complement immunotherapy company, announced today the expansion of its executive team with the addition of Dr. Robert Kim as its Chief Medical Officer. Dr. Kim will help the company optimize its drug development strategy as its clinical…
A pioneering new company based on Selvita research and utilizing novel immunological approaches to disease Edinburgh, Scotland, July 28, 2016: Epidarex Capital today announces the launch of Nodthera Limited, a new biotech company focused on the discovery and development of novel inhibitors of the NLRP3…
LOUISVILLE, Ky., June 23, 2016 – Apellis Pharmaceuticals, Inc. today announced positive results from two Phase 1 clinical trials of its complement C3 inhibitor, APL-2. The trials were randomized, double-blind, placebo-controlled, single and multiple ascending dose studies designed to assess the safety, tolerability, pharmacokinetics (PK)…
Glasgow, Scotland, UK, 20th June 2016: Mironid Ltd, a leader in cell signalling directed drug development, today announced the closing of its Series A funding round of £4.3 million ($6.2 million), which will support the Company’s internal research and preclinical development programmes, focused on degenerative…